新型靶向生物制剂ustekinumab用于自身免疫性疾病治疗  

Ustekinumab in the treatment of autoimmune diseases

作　　者：杨清锐[1] 白艳[1] 李璐[1] 张源潮[1] 

机构地区：[1]山东大学附属省立医院风湿免疫科,济南250021

出　　处：《世界临床药物》2010年第8期454-459,共6页World Clinical Drug

摘　　要：细胞因子IL-12和IL-23参与多种自身免疫性疾病的发病,两者均为含有p40亚基的异源二聚体。人源化单克隆抗体ustekinumab可与IL-12和IL-23的p40亚基结合,抑制其药理作用。本文回顾分析ustekinumab在银屑病、银屑病关节炎、克罗恩病等免疫性疾病治疗中的临床评价。IL-12 and IL-23 involve in the pathogenesis of autoimmune diseases,which are both heterodimers containing p40 subunit. As a human monoclonal antibody,ustekinumab can combine the p40 subunits of interleukin IL-12 and IL-23 and inhibit their pharmacological activity. This review summarizes the clinical evaluation on ustekinumab for the treatment of autoimmune disease,including psoriasis,psoriatic arthritis,and Crohn＇s disease.

关 键 词：USTEKINUMAB IL-12 IL-23 银屑病 银屑病关节炎 克罗恩病 

分 类 号：R593.2[医药卫生—内科学] R979.5[医药卫生—临床医学]